Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Walt Disney Co (DIS) vs Nuvalent Inc (NUVL) Price & Performance

Walt Disney CoTrade
Nuvalent IncTrade

Price performance (Past 24H)

Key statistics

Walt Disney Co vs Nuvalent Inc — how do they compare? Walt Disney Co trades at $96.7 (market cap $166.48B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Walt Disney Co is far larger — about 17× Nuvalent Inc's market cap, and Walt Disney Co pays a 1.56% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.

DISNUVL
Market Cap
$166.48B$9.81B
Volume
7,546,013
Sector
MediaTechnology
52-Week High
$122.94$123.96
52-Week Low
$92.40$72.16
Enterprise Value
$208.16B$8.52B
Dividend Yield
1.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Walt Disney Co

Disney (DIS) trades at $96.01, up 0.4% today, with a bearish technical signal but strong fundamentals including three consecutive quarterly EPS beats. Revenue grew to $94.43B in 2025 with net income surging to $12.40B. The stock shows a P/E of 15.34 and P/S of 1.77, trading below the consensus price target of $125.60. Recent news highlights advertising opportunities from major events like the Super Bowl, though box office performance for new Star Wars film raises concerns.

Outlook remains positive with analyst consensus at Buy (61.9%) and a 31% upside to target, driven by earnings momentum and theme park investments. Risks include regulatory disputes with the FCC, streaming competition, and film profitability. Cash flow trends show operational strength but negative net flows from high investing activity.

Nuvalent Inc

Nuvalent (NUVL) trades at $123.94, showing minimal daily movement with a 0.03% gain. The stock is in focus following GSK's proposed acquisition at $124 per share, announced June 2026. Technically, the price is at the acquisition offer level with a bullish moving average signal but overbought RSI readings. Fundamentally, the company reports significant losses with negative ROE and ROA, while cash flow remains supported by financing activities.

The investment outlook is dominated by the pending acquisition, limiting upside beyond the offer price. Key risks include deal completion uncertainty and ongoing operational losses. Analyst sentiment is mixed with a slight hold bias, reflecting caution until transaction closure. Shareholder value hinges on successful deal execution amid financial challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Walt Disney Co

The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.

Read more on DIS

About Nuvalent Inc

Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.

Read more on NUVL